Effects of ACLY Inhibition on Body Weight Distribution: A Drug Target Mendelian Randomization Study.

Dipender Gill, Marie-Joe Dib, Rubinder Gill, Stefan R Bornstein, Stephen Burgess, Andreas L Birkenfeld

Abstract read

In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Human genetics suggests differing causal pathways from HMGCR inhibition to coronary artery disease and type 2 diabetes.International journal of epidemiology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dipender GillDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK.ORCID 0000-0001-7312-7078

Marie-Joe DibDivision of Cardiovascular Medicine, Perelman School of Advanced Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-7591-5684

Rubinder GillPrimula Group Ltd., London N8 0RL, UK.

Stefan R BornsteinDepartment of Internal Medicine III, University Clinic, Technical University Dresden, D-01062 Dresden, Germany.

Stephen BurgessMRC Biostatistics Unit, University of Cambridge, Cambridge CB2 0SR, UK.

Andreas L BirkenfeldGerman Center for Diabetes Research (DZD), D-85764 Neuherberg, Germany.ORCID 0000-0003-1407-9023

Funding

Wellcome Trust 225790

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ATP Citrate (pro-S)-LyaseBody WeightCholesterol, LDLDiabetes Mellitus, Type 2Mendelian Randomization AnalysisPolymorphism, Single NucleotideHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesATP Citrate (pro-S)-LyaseCholesterol, LDLHMGCR protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesACLYMendelian randomizationmetabolic diseasetype 2 diabetes mellitus

Identifiers

PMID39202419

DOI10.3390/genes15081059

PMCPMC11353272

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.